CTLA4 and hereditary clear cell renal cell carcinoma: On the contrary, immunotherapy using anti-PD-1/PD-L1 agents and anti-cytotoxic T-lymphocyte associated protein-4 (CTLA-4) have shown promising and encouraging results in other malignancies including melanoma, lung cancer, renal cell carcinoma, and bladder cancer [41].